In the print version of the article listed above, there is an inconsistency in Table 1 on page 8. The weights given in the row summarizing changes in body weight should have been provided in kilograms instead of pounds, given that all weight data discussed in the article was expressed as kilograms. The corrected table row appears below:
TABLE 1.
Summary of Efficacy and Safety of Canagliflozin as Add-On to Metformin, Metformin Plus Sulfonylurea, and Insulin in Patients With Type 2 Diabetes Over 52 Weeks (3,30–33,50,53)
| Canagliflozin as: | |||
| Add-on to MET | Add-on to MET + SU | Add-on to insulin | |
| Changes in key efficacy parameters | |||
| Body weight (kg) | GLIM | PBO | PBO |
| Baseline: 86.6 | Baseline: 90.8 | Baseline: 97.7 | |
| Change: +1.0% (+0.7) | Change: –0.9% (–1.0) | Change: +0.1% (+0.1) | |
| CANA 100 mg | CANA 100 mg | CANA 100 mg | |
| Baseline: 86.8 | Baseline: 93.5 | Baseline: 96.9 | |
| Change: –4.2% (–3.7) | Change: –2.2% (–2.0) | Change: –2.4% (–2.3) | |
| CANA 300 mg | CANA 300 mg | CANA 300 mg | |
| Baseline: 86.6 | Baseline: 93.5 | Baseline: 96.7 | |
| Change: –4.7% (–4.0) | Change: –3.2% (–3.1) | Change: –3.1% (–3.0) | |
| SITA | SITA | ||
| Baseline: 87.6 | Baseline: 89.6 | ||
| Change: –1.3% (–1.2) | Change: +0.3% (+0.1) | ||
| CANA 100 mg | CANA 300 mg | ||
| Baseline: 88.7 | Baseline: 87.6 | ||
| Change: –3.8% (–3.3) | Change: –2.5% (–2.3) | ||
| CANA 300 mg | |||
| Baseline: 85.4 | |||
| Change: –4.2% (–3.7) | |||
CANA, canagliflozin; GLIM, glimepiride; MET, metformin; PBO, placebo; SITA, sitagliptin; SU, sulfonylurea.
The online version reflects these changes.